4:36 PM
 | 
Nov 06, 2018
 |  BC Extra  |  Company News

Management tracks: Five Prime, Alder

Five Prime Therapeutics Inc. (NASDAQ:FPRX) hired David Smith as EVP and CFO, effective Nov. 26. He will replace Linda Rubinstein, who was interim CFO of the cancer company. Smith was COO of IntegenX Inc. until its acquisition this year by Thermo Fisher Scientific Inc. (NYSE:TMO).

Metabolic company Jnana Therapeutics Inc. (Boston, Mass.) named co-founder and President Joanne Kotz as CEO. She succeeds board member Amir Nashat, who was interim CEO. Jnana launched last December with a $50 million series A round from Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate.

Neurology company Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) said it is seeking a new chief commercial officer to replace Chief Commercial Officer and EVP of Corporate Strategy Elisabeth Sandoval. In an SEC filing, the company said Sandoval will continue in both roles until March 31, 2019, unless she is terminated for cause or until a new chief commercial officer is hired.

Peptide company Bicycle Therapeutics Ltd. (Cambridge, U.K) hired Phil Jeffrey as SVP of preclinical development. He was head of translational sciences at Pfizer Inc. (NYSE:PFE).

The non-profit International Biomedical Research Alliance appointed Tom Heyman to its board. He is president at Johnson & Johnson Innovation - JJDC Inc, and he leads the J&J Venture Capital Group.

Oberland Capital Management LLC (New York, N.Y.) hired Cecilia Gonzalo as a partner and promoted Michael Bloom to partner from principal. Gonzalo was a managing director focused on biopharmaceutical investments at Vatera Healthcare Partners. Oberland closed an $800 million healthcare fund in September.

H.C. Wainwright hired Douglas Tsao as a managing director of equity research. He was a senior equity research analyst at Barclays.

Roth Capital Partners hired Jerry Isaacson as a managing director and senior research analyst covering biotechnology and emerging therapeutics. He was director of research and a senior analyst at LifeSci Capital.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD